290 related articles for article (PubMed ID: 30225933)
1. Severity in polycystic liver disease is associated with aetiology and female gender: Results of the International PLD Registry.
van Aerts RMM; Kievit W; de Jong ME; Ahn C; Bañales JM; Reiterová J; Nevens F; Drenth JPH
Liver Int; 2019 Mar; 39(3):575-582. PubMed ID: 30225933
[TBL] [Abstract][Full Text] [Related]
2. Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease.
Chebib FT; Jung Y; Heyer CM; Irazabal MV; Hogan MC; Harris PC; Torres VE; El-Zoghby ZM
Nephrol Dial Transplant; 2016 Jun; 31(6):952-60. PubMed ID: 26932689
[TBL] [Abstract][Full Text] [Related]
3. Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis.
Sierks D; Schönauer R; Friedrich A; Hantmann E; de Fallois J; Linder N; Fischer J; Herber A; Bergmann C; Berg T; Halbritter J
JHEP Rep; 2022 Nov; 4(11):100579. PubMed ID: 36246085
[TBL] [Abstract][Full Text] [Related]
4. Genetic Analysis of Severe Polycystic Liver Disease in Japan.
Mizuno H; Besse W; Sekine A; Long KT; Kurihara S; Oba Y; Yamanouchi M; Hasegawa E; Suwabe T; Sawa N; Ubara Y; Somlo S; Hoshino J
Kidney360; 2024 May; ():. PubMed ID: 38689396
[TBL] [Abstract][Full Text] [Related]
5. Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.
Porath B; Gainullin VG; Cornec-Le Gall E; Dillinger EK; Heyer CM; Hopp K; Edwards ME; Madsen CD; Mauritz SR; Banks CJ; Baheti S; Reddy B; Herrero JI; Bañales JM; Hogan MC; Tasic V; Watnick TJ; Chapman AB; Vigneau C; Lavainne F; Audrézet MP; Ferec C; Le Meur Y; Torres VE; ; ; Harris PC
Am J Hum Genet; 2016 Jun; 98(6):1193-1207. PubMed ID: 27259053
[TBL] [Abstract][Full Text] [Related]
6. Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing.
Lanktree MB; Haghighi A; Guiard E; Iliuta IA; Song X; Harris PC; Paterson AD; Pei Y
J Am Soc Nephrol; 2018 Oct; 29(10):2593-2600. PubMed ID: 30135240
[TBL] [Abstract][Full Text] [Related]
7. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH;
Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403
[TBL] [Abstract][Full Text] [Related]
8. Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease.
Martin WP; Vaughan LE; Yoshida K; Takahashi N; Edwards ME; Metzger A; Senum SR; Masyuk TV; LaRusso NF; Griffin MD; El-Zoghby Z; Harris PC; Kremers WK; Nagorney DM; Kamath PS; Torres VE; Hogan MC
Mayo Clin Proc Innov Qual Outcomes; 2019 Jun; 3(2):149-159. PubMed ID: 31193902
[TBL] [Abstract][Full Text] [Related]
9. Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases.
Cornec-Le Gall E; Torres VE; Harris PC
J Am Soc Nephrol; 2018 Jan; 29(1):13-23. PubMed ID: 29038287
[TBL] [Abstract][Full Text] [Related]
10. Center is an important indicator for choice of invasive therapy in polycystic liver disease.
D'Agnolo HM; Kievit W; van Munster KN; van der Laan JJ; Nevens F; Drenth JP
Transpl Int; 2017 Jan; 30(1):76-82. PubMed ID: 27732751
[TBL] [Abstract][Full Text] [Related]
11. The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease.
D'Agnolo HMA; Casteleijn NF; Gevers TJG; de Fijter H; van Gastel MDA; Messchendorp AL; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JFM; Zietse R; Gansevoort RT; Drenth JPH
Am J Nephrol; 2017; 46(3):239-248. PubMed ID: 28881341
[TBL] [Abstract][Full Text] [Related]
12. Isolated polycystic liver disease as a distinct genetic disease, unlinked to polycystic kidney disease 1 and polycystic kidney disease 2.
Pirson Y; Lannoy N; Peters D; Geubel A; Gigot JF; Breuning M; Verellen-Dumoulin C
Hepatology; 1996 Feb; 23(2):249-52. PubMed ID: 8591848
[TBL] [Abstract][Full Text] [Related]
13. Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.
Gevers TJ; Nevens F; Torres VE; Hogan MC; Drenth JP
Liver Int; 2016 Apr; 36(4):595-602. PubMed ID: 26481454
[TBL] [Abstract][Full Text] [Related]
14. Heterozygosity of ALG9 in Association with Autosomal Dominant Polycystic Liver Disease.
Boerrigter MM; Duijzer R; Te Morsche RHM; Drenth JPH
Genes (Basel); 2023 Sep; 14(9):. PubMed ID: 37761895
[TBL] [Abstract][Full Text] [Related]
15. The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression.
Neijenhuis MK; Kievit W; Perrone RD; Sloan JA; Erwin P; Murad MH; Gevers TJG; Hogan MC; Drenth JPH
BMC Nephrol; 2017 May; 18(1):169. PubMed ID: 28545401
[TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial.
D'Agnolo HM; Kievit W; Takkenberg RB; Riaño I; Bujanda L; Neijenhuis MK; Brunenberg EJ; Beuers U; Banales JM; Drenth JP
J Hepatol; 2016 Sep; 65(3):601-7. PubMed ID: 27212247
[TBL] [Abstract][Full Text] [Related]
17. Clinical profile of autosomal dominant polycystic liver disease.
Qian Q; Li A; King BF; Kamath PS; Lager DJ; Huston J; Shub C; Davila S; Somlo S; Torres VE
Hepatology; 2003 Jan; 37(1):164-71. PubMed ID: 12500201
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of autosomal-dominant polycystic liver disease in Olmsted county.
Suwabe T; Chamberlain AM; Killian JM; King BF; Gregory AV; Madsen CD; Wang X; Kline TL; Chebib FT; Hogan MC; Kamath PS; Harris PC; Torres VE
JHEP Rep; 2020 Dec; 2(6):100166. PubMed ID: 33145487
[TBL] [Abstract][Full Text] [Related]
19. Sex, Genotype, and Liver Volume Progression as Risk of Hospitalization Determinants in Autosomal Dominant Polycystic Liver Disease.
Schönauer R; Sierks D; Boerrigter M; Jawaid T; Caroff L; Audrezet MP; Friedrich A; Shaw M; Degenhardt J; Forberger M; de Fallois J; Bläker H; Bergmann C; Gödiker J; Schindler P; Schlevogt B; Müller RU; Berg T; Patterson I; Griffiths WJ; Sayer JA; ; Popp B; Torres VE; Hogan MC; Somlo S; Watnick TJ; Nevens F; Besse W; Cornec-Le Gall E; Harris PC; Drenth JPH; Halbritter J
Gastroenterology; 2024 May; 166(5):902-914. PubMed ID: 38101549
[TBL] [Abstract][Full Text] [Related]
20. Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease.
Kim H; Park HC; Ryu H; Kim K; Kim HS; Oh KH; Yu SJ; Chung JW; Cho JY; Kim SH; Cheong HI; Lee K; Park JH; Pei Y; Hwang YH; Ahn C
PLoS One; 2015; 10(12):e0144526. PubMed ID: 26641645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
